Two recent articles about skin cancer feature MSK researchers.

The first, The Atlantic piece “AI-Driven Dermatology Could Leave Dark-Skinned Patients Behind,” discusses how researchers need to diversify the skin colors represented in image repositories being used to develop machine-learning algorithms that identify cancerous skin lesions. MSK dermatologist Dr. Allan C. Halpern states that the International Skin Imaging Collaboration, for which he is a spokesperson, is working to do just that.

The second, The New York Times article, “Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain,” describes a recent study of 94 melanoma patients with tumors that spread to their brains. It found that two immunotherapy treatments given in combination, ipilimumab and nivolumab, reduced tumor size and prolonged life for many of the patients. The article quotes MSK’s Dr. Jedd Wolchok, who has already applied the findings to treating his own patients.